This follow-up report is submitted to the fda in accord with applicable regulations - and as indicated by terumo cardiovascular system in the initial report submitted to the fda on november 4, 2016.
(b)(4).
The sample was not returned for evaluation.
A retention sample from the same product code/lot number combination was visually inspected and confirmed to not have any damages or anomalies, specifically with the sampling manifold.
A review of the device history record revealed no manufacturing anomalies.
A definitive root cause could not be determined; therefore, this complaint is not confirmed.
All available information has been placed on file in quality management for appropriate tracking, trending and follow up.
|